Terms: = Prostate cancer AND NBN, AT-V2, 4683, ENSG00000104320, ATV, FLJ10155, NBS, AT-V1, MGC87362, NBS1
92 results:
1. Targeted Ultrasound Nanobubbles Therapy for prostate cancer via Immuno-Sonodynamic Effect.
Huang X; Chen Y; Zhong F; Gui B; Hu Y; Guo Y; Deng Q; Zhou Q
Int J Nanomedicine; 2024; 19():2793-2806. PubMed ID: 38525011
[TBL] [Abstract] [Full Text] [Related]
2. Identification of Genes with Rare Loss of Function Variants Associated with Aggressive prostate cancer and Survival.
Saunders EJ; Dadaev T; Brook MN; Wakerell S; Govindasami K; Rageevakumar R; Hussain N; Osborne A; Keating D; Lophatananon A; Muir KR; ; Darst BF; Conti DV; Haiman CA; Antoniou AC; Eeles RA; Kote-Jarai Z
Eur Urol Oncol; 2024 Apr; 7(2):248-257. PubMed ID: 38458890
[TBL] [Abstract] [Full Text] [Related]
3. Opportunistic screening with multiphase contrast-enhanced dual-layer spectral CT for osteoblastic lesions in prostate cancer compared with bone scintigraphy.
Liu MC; Ho CC; Lin YT; Chai JW; Hung SW; Wu CH; Li JR; Liu YJ
Sci Rep; 2024 Mar; 14(1):5310. PubMed ID: 38438474
[TBL] [Abstract] [Full Text] [Related]
4. Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathway.
Mahlow J; Barry M; Albertson DJ; Jo YJ; Balatico M; Seasor T; Gebrael G; Kumar SA; Sayegh N; Tripathi N; Agarwal N; Swami U; Sirohi D
Hum Pathol; 2024 Feb; 144():28-33. PubMed ID: 38278448
[TBL] [Abstract] [Full Text] [Related]
5. Germline DNA Damage Response Gene Mutations in Localized prostate cancer.
Januskevicius T; Vaicekauskaite I; Sabaliauskaite R; Matulevicius A; Vezelis A; Ulys A; Jarmalaite S; Jankevicius F
Medicina (Kaunas); 2023 Dec; 60(1):. PubMed ID: 38256334
[No Abstract] [Full Text] [Related]
6. Quantification of extravasation and binding of PSMA-targeted nanobubbles by modelling the second-wave phenomenon.
Chen C; Perera R; Mischi M; Kolios M; Exner A; Turco S
Mol Imaging Biol; 2024 Apr; 26(2):253-263. PubMed ID: 38151581
[TBL] [Abstract] [Full Text] [Related]
7. Polygenic Risk Score Modifies prostate cancer Risk of Pathogenic Variants in Men of African Ancestry.
Hughley RW; Matejcic M; Song Z; Sheng X; Wan P; Xia L; Hart SN; Hu C; Yadav S; Lubmawa A; Kiddu V; Asiimwe F; Amanya C; Mutema G; Job K; Ssebakumba MK; Ingles SA; Hamilton AS; Couch FJ; Watya S; Conti DV; Darst BF; Haiman CA
Cancer Res Commun; 2023 Dec; 3(12):2544-2550. PubMed ID: 38014910
[TBL] [Abstract] [Full Text] [Related]
8.
Ma XK; Liu TL; Ren YN; Ma XP; Yao Y; Hou XG; Ding J; Wang F; Huang HF; Zhu H; Yang Z
Acta Pharmacol Sin; 2024 Feb; 45(2):436-448. PubMed ID: 37749238
[TBL] [Abstract] [Full Text] [Related]
9. Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive prostate cancer.
Darst BF; Saunders E; Dadaev T; Sheng X; Wan P; Pooler L; Xia LY; Chanock S; Berndt SI; Wang Y; Patel AV; Albanes D; Weinstein SJ; Gnanapragasam V; Huff C; Couch FJ; Wolk A; Giles GG; Nguyen-Dumont T; Milne RL; Pomerantz MM; Schmidt JA; Travis RC; Key TJ; Stopsack KH; Mucci LA; Catalona WJ; Marosy B; Hetrick KN; Doheny KF; MacInnis RJ; Southey MC; Eeles RA; Wiklund F; Conti DV; Kote-Jarai Z; Haiman CA
JAMA Oncol; 2023 Nov; 9(11):1514-1524. PubMed ID: 37733366
[TBL] [Abstract] [Full Text] [Related]
10. Genetic landscape of homologous recombination repair genes in early-onset/familial prostate cancer patients.
Paulo P; Cardoso M; Brandão A; Pinto P; Falconi A; Pinheiro M; Cerveira N; Silva R; Santos C; Pinto C; Peixoto A; Maia S; Teixeira MR
Genes Chromosomes Cancer; 2023 Dec; 62(12):710-720. PubMed ID: 37436117
[TBL] [Abstract] [Full Text] [Related]
11. Neurocognitive test performance following cancer among middle-aged and older adults in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) and the SOL-Investigation of Neurocognitive Aging Ancillary Study.
Parada H; Pichardo MS; Gallo LC; Talavera GA; McDaniels-Davidson C; Penedo FJ; Lee DJ; Tarraf W; Garcia TP; Daviglus ML; González HM
Cancer Med; 2023 May; 12(10):11860-11870. PubMed ID: 36999972
[TBL] [Abstract] [Full Text] [Related]
12. OWL: an optimized and independently validated machine learning prediction model for lung cancer screening based on the UK Biobank, PLCO, and NLST populations.
Pan Z; Zhang R; Shen S; Lin Y; Zhang L; Wang X; Ye Q; Wang X; Chen J; Zhao Y; Christiani DC; Li Y; Chen F; Wei Y
EBioMedicine; 2023 Feb; 88():104443. PubMed ID: 36701900
[TBL] [Abstract] [Full Text] [Related]
13. Cell-Free DNA Sequencing Reveals Gene Variants in DNA Damage Repair Genes Associated with Prognosis of prostate cancer Patients.
Lieb V; Abdulrahman A; Weigelt K; Hauch S; Gombert M; Guzman J; Bellut L; Goebell PJ; Stöhr R; Hartmann A; Wullich B; Taubert H; Wach S
Cells; 2022 Nov; 11(22):. PubMed ID: 36429046
[TBL] [Abstract] [Full Text] [Related]
14. A Two-Step Frailty Assessment Strategy in Older Patients With Solid Tumors: A Decision Curve Analysis.
González Serrano A; Laurent M; Barnay T; Martínez-Tapia C; Audureau E; Boudou-Rouquette P; Aparicio T; Rollot-Trad F; Soubeyran P; Bellera C; Caillet P; Paillaud E; Canouï-Poitrine F
J Clin Oncol; 2023 Feb; 41(4):826-834. PubMed ID: 36306481
[TBL] [Abstract] [Full Text] [Related]
15. Genomic characterization of metastatic castration-resistant prostate cancer patients undergoing PSMA radioligand therapy: A single-center experience.
Satapathy S; Das CK; Aggarwal P; Sood A; Parihar AS; Singh SK; Mittal BR
Prostate; 2023 Feb; 83(2):169-178. PubMed ID: 36259290
[TBL] [Abstract] [Full Text] [Related]
16. Ex vivo γH2AX assay for tumor radiosensitivity in primary prostate cancer patients and correlation with clinical parameters.
Marinescu IM; Rogg M; Spohn S; von Büren M; Kamps M; Jilg CA; Fountzila E; Papadopoulou K; Ceci L; Bettermann A; Ruf J; Benndorf M; Adebahr S; Zips D; Grosu AL; Schell C; Zamboglou C
Radiat Oncol; 2022 Oct; 17(1):163. PubMed ID: 36199143
[TBL] [Abstract] [Full Text] [Related]
17. Molecular Profile Changes in Patients with Castrate-Resistant prostate cancer Pre- and Post-Abiraterone/Prednisone Treatment.
Sicotte H; Kalari KR; Qin S; Dehm SM; Bhargava V; Gormley M; Tan W; Sinnwell JP; Hillman DW; Li Y; Vedell PT; Carlson RE; Bryce AH; Jimenez RE; Weinshilboum RM; Kohli M; Wang L
Mol Cancer Res; 2022 Dec; 20(12):1739-1750. PubMed ID: 36135372
[TBL] [Abstract] [Full Text] [Related]
18. Pharmacokinetic modeling of PSMA-targeted nanobubbles for quantification of extravasation and binding in mice models of prostate cancer.
Chen C; Perera R; Kolios MC; Wijkstra H; Mischi M; Exner AA; Turco S
Med Phys; 2022 Oct; 49(10):6547-6559. PubMed ID: 36049109
[TBL] [Abstract] [Full Text] [Related]
19. Germline Variant Spectrum Among African American Men Undergoing prostate cancer Germline Testing: Need for Equity in Genetic Testing.
Giri VN; Hartman R; Pritzlaff M; Horton C; Keith SW
JCO Precis Oncol; 2022 May; 6(1):e2200234. PubMed ID: 35666082
[TBL] [Abstract] [Full Text] [Related]
20. Germline genetics of prostate cancer.
Khan HM; Cheng HH
Prostate; 2022 Aug; 82 Suppl 1(Suppl 1):S3-S12. PubMed ID: 35657157
[TBL] [Abstract] [Full Text] [Related]
[Next]
